Muller, Alexander J.
Manfredi, Mark G.
Zakharia, Yousef
Prendergast, George C.
Article History
Received: 8 August 2018
Accepted: 13 August 2018
First Online: 10 September 2018
Compliance with ethical standards
:
: G.C.P. and A.J.M. are shareholders and G.C.P. is a former compensated scientific advisor and grant recipient for New Link Genetics Corporation, a biopharmaceutical company that has licensed IDO intellectual property for clinical development from the Lankenau Institute of Medical Research, as described in U.S. Patents Nos. 7705022, 7714139, 8008281, 8058416, 8383613, 8389568, 8436151, 8476454, and 8586636. G.C.P. is a compensated scientific advisor for Kyn Therapeutics Inc. which is developing IDO/TDO/AHR pathway antagonists for cancer treatment. A.J.M. is a grant recipient and compensated scientific advisor for I-O Biotech AG which is developing IDO vaccines for cancer treatment. MM is a shareholder in Kyn Therapeutics. Y.Z. is a recipient of research and conference travel support from NewLink Genetics and an advisory board member for Amgen, Roche Diagnostics, Novartis, Eisai, Castle Bioscience, and Exelixis.